Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn:
“Excited to publish the results from our First-in-Human clinical trial with our IL-2 cytokine factories in patients with refractory recurrent ovarian cancer in Clinical Cancer Research.
Here we demonstrate the safety and preliminary efficacy of our cytokine factories. Super appreciative to all of our clinician collaborators, scientists, and the patients who participated in the trial.”
Title: First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma
Authors: Helen D. Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen, Jonathon Debonis, Juan Carlos Amador-Molina, Amanda Nash, Manish Jain, Ryan Newman, Lauren Jansen, Karen Andreas, Kelly Rangel, Travis T. Sims, Bryan Fellman, Claudio Dansky Ullmann, Oladapo Yeku, Amy J. Bregar, Andrew M. Blakely, Cara Mathews, Oleg A. Igoshin, Cara Haymaker, Jose Oberholzer, Peter Rios, Daisy Lopez, Hafsa Nasir, Ira Joshi, Rima Chakrabarti, Omid Veiseh, Amir A. Jazaeri, Shannon N. Westin
Other articles about Rice University on OncoDaily.